Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

$1M For Luxturna? ICER Says Big Discount Needed To Be Cost Effective

Nov 15 2017

• By Jessica Merrill

Institute For Clinical And Economic Review

Related Content

Spark's Gene Therapy Luxturna Sails Through US FDA Panel

Oct 13 2017

ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments

Aug 10 2017

Spark Stands By $1M Or More Price Possibility For Luxturna

Nov 07 2017

Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting

Oct 13 2017

Related Companies

Spark Therapeutics, Inc.

Novartis AG

Gilead Sciences, Inc.

Kite Pharma, Inc.

Additional Topics

Reimbursement Pricing Strategies Rare Diseases Cost Effectiveness Policy BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window